SVRA (Savara Inc) Sof foyda

SVRA (Savara) - kompaniyaning tovar belgisi

Savara Inc. (SVRA) kompaniyasining, foydasi -0.14 miqdorini tashkil etuvchi, ushbu narxlar grafigida ko'rsatilgan bozor tendentsiyasi, noyob o'pka terapiyalaridagi tor ixtisoslashuvi va FDA qarorlariga bog'liqligi sababli zaif bo'lgan biofarmatsevtika biznesi dinamikasini aks ettiradi. Noyob reagentlarni yetkazib berish va patent himoyasini murakkablashtiradigan geosiyosiy keskinliklar kompaniyaning barqarorligiga putur yetkazmoqda. Asosiy muvaffaqiyat molgramostimning tasdiqlanishiga bog'liq, ammo ushbu yagona agentni bozorga olib chiqish bilan bog'liq tijorat risklari sezarli darajada qolmoqda.

SVRA (Savara Inc.) Sof foyda tarixi 04.07.2022dan 31.10.2026gacha

Savara (SVRA) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Savara Pharma|SVRA - Tahlilchilar konsensus prognozi
- biznesning bozor baholash ko'rsatkichlari:
Bozor kapitallashuvi Savara Pharma|SVRA - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Aksiyaning buxgalteriya qiymati Savara|SVRA - Balans kapitallashuvi|Balans qiymatiga nisbatan bozor kapitallashuvi savarapharma.com|SVRA - Kompaniyaning jami aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Savara Inc.|SVRA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Savara Inc|SVRA - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Savara Pharma|SVRA - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi Savara|Shoshilinch likvidlik savarapharma.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
SVRA - Kompaniyaning sof foydasi
Kompaniyaning jamlanma tahlili:Savara Inc.
Savara Corp asosiy tovari

Savara Inc. (SVRA) o'zining asosiy kamyob kasalliklar dori vositasini ro'yxatdan o'tkazish uchun yuqori operatsion tayyorgarlikni namoyish etmoqda. Kompaniyaning foydasini tahlil qilib, investor biznesning kunlik moliyaviy natijalari bo'yicha bozor konsensusini ko'radi. Ushbu ko'rsatkich kapital to'planishining real sur'atini aks ettirib, foyda dinamikasi orqali fundamental barqarorlikni ochib beradi. Barqaror o'sish jarayonlar shaffofligini tasdiqlaydi va aktiv uchun haddan tashqari ko'p to'lov qilish riskini yo'q qiladi. Bunday ko'rsatkichlar ushbu biotexnologiya kompaniyasining biznes modelining mustahkamligini tasdiqlaydi.

Asosiy raqobatchilar

Sof daromad argenx BVBA|BNTX (BioNTech SE) - Sof foyda|Sof foyda Abivax Pharma|Sof daromad ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Yakuniy foyda|Sof foyda IMVT (Immunovant Corp)|Sof moliyaviy natija Kiniksa Corp (KNSA)|GRFS - Kompaniyaning sof foydasi|adaptivebiotech.com (ADPT) - Sof daromad|Celldex Therapeutics, Inc. (CLDX) - Kompaniyaning sof foydasi|Sof daromad Aurinia Pharmaceuticals Inc|Sof daromad BCRX|Sof foyda Vera Corp|Kompaniyaning sof foydasi Dianthus Therapeutics (DNTH)|pharvaris.com - Kompaniya foydasi|Sof foyda ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Kompaniyaning sof daromadi|PGEN - Kompaniyaning sof foydasi|Sof moliyaviy natija Pharming Corp PHAR|NKTR: Sof foyda|upstreambio.com (UPB) - Sof foyda|Sof daromad ZBIO|Kompaniyaning sof foydasi IMNM|Sof foyda GOSS|Sof foyda KalVista Corp (KALV)|Kompaniyaning sof foydasi Septerna Inc SEPN|Yakuniy foyda PVLA|Rigel Pharmaceuticals, Inc. - Sof foyda|ANAB - Sof foyda|ATXS (Astria Pharma) - Sof daromad|enGene Corp - Yakuniy foyda|RAPT (RAPT Therapeutics, Inc.) - Sof foyda|Aerovate (JBIO) - Sof moliyaviy natija|Kompaniyaning sof foydasi Aclaris Therapeutics, Inc. (ACRS)|Kyverna Therapeutics Inc. - Kompaniya foydasi|Sof foyda TLSA (Tiziana Life Sciences PLC)|CABA - Sof daromad|VTYX: Sof daromad|Sof moliyaviy natija theratech.com THTX|Avalo Therapeutics (AVTX) - Kompaniyaning sof foydasi|ELDN - Sof moliyaviy natija|Sof daromad AGEN|Kompaniyaning sof foydasi CLYM|Kompaniyaning sof foydasi Zura Bio Limited (ZURA)|ATYR (atyrpharma.com) - Yakuniy foyda|Sof foyda ADAG (Adagene Inc.)|Sof foyda ImageneBio IMA|STTK - Kompaniyaning sof foydasi|Soliqdan keyingi foyda EQ|CNTB: Sof foyda|Immunic - Yakuniy foyda|ATRA (Atara Biotherapeutics, Inc.) - Sof foyda|Sof foyda InflaRx GmbH|Kompaniyaning sof foydasi X4 Pharma (XFOR)|ACET (adicetbio.com) - Yakuniy foyda|Kompaniyaning sof foydasi Celularity CELU|INMB - Sof daromad|Barinthus Biotherapeutics plc - Sof foyda|KZR - Sof foyda|SABS (SAB Biotherapeutics, Inc) - Sof daromad|Akari Therapeutics, Plc - Yakuniy foyda|ENLV (Enlivex Therapeutics Ltd) - Sof foyda|Q32 Bio Corp (QTTB) - Sof moliyaviy natija|Kompaniyaning sof foydasi GeoVax (GOVX)|Sof daromad Edesa Biotech Inc EDSA|Kompaniyaning sof foydasi iBio Corp IBIO|CARM - Sof daromad|XTLB: Sof daromad|BOLT - Sof foyda|hcwbiologics.com (HCWB) - Kompaniyaning sof foydasi|Kompaniya foydasi APVO|AIM (AIM ImmunoTech) - Sof foyda|Kompaniyaning sof daromadi Aditxt Corp ADTX|Kompaniyaning sof foydasi GRI Bio, Inc. (GRI)|Sof moliyaviy natija xortx.com|Sof foyda HIND (Vyome Holdings)|Sof foyda Revelation Biosciences Inc REVB|INDP: Sof daromad|SCNI: Kompaniyaning sof foydasi|CALI: Sof foyda|Affimed N.V. (AFMD) - Sof foyda|Kompaniyaning sof foydasi Allakos Inc|HOOK: Yakuniy foyda|Sof foyda IGMS|Sof foyda iTeos Pharma (ITOS)|Ocean Biomedical, Inc. - Sof daromad|Yakuniy foyda TCBP|Third Harmonic Bio, Inc. - Sof foyda